Toggle navigation
About
Abstract
Editorial Board
Publication Schedule
Subscription & Newsletter
Contact
Issue
23-4
Table of Contents
Editors Selection
Glaucoma Dialogue
Glaucoma Opinion
Abstracts
Abstracts
Abstracted Journals
Classification List
Index of Authors
Search
Home
Abstracts
Index of Authors
Author #113359
advertisement
Schulte-Merker S
20
Showing records 1 to 20 |
Display all abstracts from
Schulte-Merker S
108470
Svep1 is a binding ligand of Tie1 and affects specific aspects of facial lymphatic development in a Vegfc-independent manner
Hußmann M
eLife
2023; 12:
107738
The novel role of lymphatic vessels in the pathogenesis of ocular diseases
Clahsen T
Progress in Retinal and Eye Research
2023; 0: 101157
108470
Svep1 is a binding ligand of Tie1 and affects specific aspects of facial lymphatic development in a Vegfc-independent manner
Schulte D
eLife
2023; 12:
107738
The novel role of lymphatic vessels in the pathogenesis of ocular diseases
Hadrian K; Notara M
Progress in Retinal and Eye Research
2023; 0: 101157
108470
Svep1 is a binding ligand of Tie1 and affects specific aspects of facial lymphatic development in a Vegfc-independent manner
Weischer S
eLife
2023; 12:
107738
The novel role of lymphatic vessels in the pathogenesis of ocular diseases
Schlereth SL
Progress in Retinal and Eye Research
2023; 0: 101157
108470
Svep1 is a binding ligand of Tie1 and affects specific aspects of facial lymphatic development in a Vegfc-independent manner
Carlantoni C
eLife
2023; 12:
107738
The novel role of lymphatic vessels in the pathogenesis of ocular diseases
Howaldt A
Progress in Retinal and Eye Research
2023; 0: 101157
108470
Svep1 is a binding ligand of Tie1 and affects specific aspects of facial lymphatic development in a Vegfc-independent manner
Nakajima H
eLife
2023; 12:
107738
The novel role of lymphatic vessels in the pathogenesis of ocular diseases
Prokosch V
Progress in Retinal and Eye Research
2023; 0: 101157
108470
Svep1 is a binding ligand of Tie1 and affects specific aspects of facial lymphatic development in a Vegfc-independent manner
Mochizuki N; Stainier DYR
eLife
2023; 12:
107738
The novel role of lymphatic vessels in the pathogenesis of ocular diseases
Volatier T
Progress in Retinal and Eye Research
2023; 0: 101157
108470
Svep1 is a binding ligand of Tie1 and affects specific aspects of facial lymphatic development in a Vegfc-independent manner
Zobel T
eLife
2023; 12:
107738
The novel role of lymphatic vessels in the pathogenesis of ocular diseases
Hos D
Progress in Retinal and Eye Research
2023; 0: 101157
108470
Svep1 is a binding ligand of Tie1 and affects specific aspects of facial lymphatic development in a Vegfc-independent manner
Koch M
eLife
2023; 12:
107738
The novel role of lymphatic vessels in the pathogenesis of ocular diseases
Schroedl F
Progress in Retinal and Eye Research
2023; 0: 101157
108470
Svep1 is a binding ligand of Tie1 and affects specific aspects of facial lymphatic development in a Vegfc-independent manner
Schulte-Merker S
eLife
2023; 12:
107738
The novel role of lymphatic vessels in the pathogenesis of ocular diseases
Kaser-Eichberger A
Progress in Retinal and Eye Research
2023; 0: 101157
108470
Svep1 is a binding ligand of Tie1 and affects specific aspects of facial lymphatic development in a Vegfc-independent manner
Schulte-Merker S
eLife
2023; 12:
107738
The novel role of lymphatic vessels in the pathogenesis of ocular diseases
Heindl LM; Steven P; Bosch JJ; Steinkasserer A; Rokohl AC; Rokohl AC; Liu H; Mestanoglu M; Kashkar H; Schumacher B; Kiefer F; Schulte-Merker S; Schulte-Merker S; Matthaei M; Hou Y; Fassbender S; Jantsch J; Zhang W; Enders P; Bachmann B; Bock F; Cursiefen C
Progress in Retinal and Eye Research
2023; 0: 101157
Issue
23-4
Table of Contents
Editor's Selection
PDF
EPUB
Change Issue
24-4
24-3
24-1/2
23-4
23-3
23-2
23-1
22-4
22-3
22-2
22-1
21-4
21-3
21-2
21-1
20-4
20-3
20-2
20-1
19-4
19-3
19-2
19-1
18-4
18-3
18-2
18-1
17-4
17-3
17-2
17-1
16-4
16-3
16-2
16-1
15-4
15-3
15-2
15-1
14-4
14-3
14-2
14-1
13-4
13-3
13-2
13-1
12-4
12-3
12-2
12-1
11-4
11-3
11-2
11-1
10-4
10-3
10-2
10-1
9-4
9-3
9-2
9-1
8-4
8-3
8-2
8-1
7-3
7-2
7-1
6-3
6-2
6-1
5-3
5-2
5-1
4-3
4-2
4-1
3-3
3-2
3-1
2-3
2-2
2-1
1-3
1-2
1-1
advertisement